ANIK

In the past six months, Anika Therapeutics released its Q1 2026 earnings on April 29, 2026, and Q2 2026 earnings on July 29, 2026, with Q2 results exceeding analyst expectations, showing a 16% revenue increase from Q2 2025 and a net income of $3.31 million. Following strong Q2 results, the company received a 'Buy' rating from B. Riley, with price targets raised to $21 from $18 (B. Riley) and to $21 from $17 (Barrington), resulting in a 'Moderate Buy' consensus rating. Anika Therapeutics updated its fiscal year 2027 revenue guidance to flat to 5% growth, including only products with regulatory approval. The company was dropped from the Russell 2000 Defensive Index. On June 3, 2026, the President of Anika Therapeutics exercised options to acquire 4,000 shares and subsequently sold them for an average price of $14.41 per share. Over the last 12 months, the stock price increased by 39.76%, with a year-to-date return of 56.19%, and a 3.30% increase in the past month.